Open-label Phase 1b Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer Who Have Progressed Following Chemotherapy for Advanced or Metastatic Disease.

Trial Profile

Open-label Phase 1b Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer Who Have Progressed Following Chemotherapy for Advanced or Metastatic Disease.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2015

At a glance

  • Drugs IMO 2055 (Primary) ; Cetuximab; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 09 May 2012 Result were reported in an Idera Pharmaceuticals media release.
    • 13 Oct 2011 Status changed from active, no longer recruiting to discontinued, according to ClinicalTrials.gov. EMD Serono (a division of Merck KGaA) discontinued the trial as Merck KGaA terminated their agreement with Idera to co-develop IMO 2055.
    • 07 Jul 2011 Final data analysis from the dose escalation part is ongoing, according to an Idera Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top